PIVYA® (pivmecillinam) tablets is a penicillin class antibiotic for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible bacteria.

This website is intended for US healthcare professionals only.

PIVYA HCP Hero

For your patients with uncomplicated Urinary Tract Infections (uUTIs)…

A targeted first-line option with proven outcomes.1

About PIVYA®

A Targeted Oral Treatment for Uncomplicated UTIs1,2

PIVYA (pivmecillinam) is indicated for women 18 years and older with uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.1

PIVYA (pivmecillinam) received FDA approval in April 2024 following Priority Review and designation as a Qualified Infectious Disease Product (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act. The GAIN Act was established to encourage the development of antibiotics for serious or life-threatening infections, including those caused by drug-resistant pathogens.2

With clinical efficacy demonstrated in three controlled trials and a safety and tolerability profile informed by more than 40 years of international experience with pivmecillinam, PIVYA gives US clinicians an additional oral treatment option for uUTI.1,3

What Makes PIVYA a Different Type of Beta-Lactam?

Pivmecillinam, the active ingredient in PIVYA, is the only oral beta-lactam included among first-line treatment options for uncomplicated cystitis in women in both the 2011 IDSA/ESCMID and 2026 European Association of Urology (EAU) guidelines.4,5 More recently, the 2026 IDSA guidance on the treatment of antimicrobial resistant Gram-negative infections also identified pivmecillinam as a preferred treatment option for uncomplicated UTIs caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales.6

PIVYA offers a distinct binding profile within the beta-lactam class: its active form, mecillinam, specifically targets penicillin-binding protein 2 (PBP-2), unlike most other beta-lactams, which preferentially bind PBP-1A, -1B, or -3.1 As a prodrug of mecillinam, PIVYA is converted to its active form, which is eliminated primarily through urinary excretion.1 Pivmecillinam is also recognized in the IDSA/ESCMID guideline for its low propensity for collateral damage.5

PIVYA is a β-lactam with a Unique Mechanism of Action1

Selectively binds penicillin-binding protein-2 (PBP-2), disrupting bacterial cell wall synthesis.1

PBP-2 INHIBITION: Blocks elongation (loss of rod shape)

PBP-2 Inhibition Art

How PIVYA Works

Why PIVYA?

Resistance Icon

Resistance

Find out why antibiotic treatments are not always appropriate empiric choices.

Learn More
Efficacy Icon

Efficacy/Safety

See the results of clinical trials in which PIVYA was evaluated against placebo, ibuprofen, and cephalexin.

View Data
Prescription Icon

Prescribing PIVYA

What to know about starting your patients on PIVYA.

Prescribing Guide

Help Your Patients Save on Their Prescription for PIVYA

Most eligible commercially insured patients pay between $0 and $15 using the PIVYA copay savings card.

PIVYA Copay Card

Request samples for your office

Click the button below to fill out an online form to receive a free sample of PIVYA.

In compliance with the Prescription Drug Marketing Act regulations, incomplete request forms cannot be processed and samples will not be delivered.

References:
  1. PIVYA (pivmecillinam) Prescribing Information. Alembic Therapeutics; 2025.
  2. US Food and Drug Administration. FDA approves new treatment for uncomplicated urinary tract infections. Published April 24, 2024. Accessed October 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections.
  3. Kaye KS, et al. Clin Infect Dis. 2025;80:280-299.
  4. Kranz J, et al. Eur Urol. 2026;90(4):413-429.
  5. Gupta K, et al. Clin Infect Dis. 2011;52(5):e103-e120.
  6. Tamma PD, et al. Clin Infect Dis. 2026; doi:10.1093/cid/ciag481.